原文：Primary central nervous system lymphoma is a rare but aggressive brain malignancy. It is associated with poor prognosis even with the current standard of care. The aim of this study was to evaluate the effect and tolerability of blood-brain barrier disruption treatment combined with high-dose treatment with autologous stem cell transplantation as consolidation on primary central nervous system lymphoma patients. We performed a prospective phase II study for 25 patients with previously untreated primary central nervous system lymphoma. The blood-brain barrier disruption treatment was initiated 3-4 weeks after the MATRix regimen using the previously optimized therapy protocol. Briefly, each chemotherapy cycle included two subsequent intra-arterial blood-brain barrier disruption treatments on days 1 and 2 via either one of the internal carotid arteries or vertebral arteries. Patients received the therapy in 3-week intervals. The treatment was continued for two more courses after achieving a maximal radiological response to the maximum of six courses. The complete treatment response was observed in 88.0% of the patients. At the median follow-up time of 30 months, median progression-free and overall survivals were not reached. The 2-year overall and progression-free survival rates were 67.1% and 70.3%, respectively. Blood-brain barrier disruption treatment is a promising option for primary central nervous system lymphoma with an acceptable toxicity profile. 简体中文：原发性中枢神经系统淋巴瘤是一种罕见但具有侵袭性的脑部恶性肿瘤。即使采用目前的标准治疗，该病也预后不良。本研究的目的是评估血脑屏障破坏治疗联合自体造血干细胞移植高剂量治疗作为原发性中枢神经系统淋巴瘤患者巩固治疗的疗效和耐受性。我们对25例先前未接受治疗的原发性中枢神经系统淋巴瘤患者进行了前瞻性II期研究。血脑屏障破坏治疗是在采用先前优化的治疗方案下的MATRix方案3-4周后开始进行的。简言之，每个化疗周期包括两个连续的动脉内血脑屏障破坏治疗，在第1天和第2天通过内颈动脉或椎动脉的任意一个进行。患者每3周接受一次治疗。在达到最大放射学反应后，治疗将继续两个疗程，最多进行六个疗程。88.0%的患者观察到完全治疗反应。在中位随访时间为30个月时，中位无进展生存期和总生存期尚未达到。2年总体生存率和无进展生存率分别为67.1%和70.3%。血脑屏障破坏治疗是一种具有可接受毒副作用的原发性中枢神经系统淋巴瘤的有前景的选择。

Primary central nervous system lymphoma is a rare but aggressive brain malignancy. It is associated with poor prognosis even with the current standard of care. The aim of this study was to evaluate the effect and tolerability of blood-brain barrier disruption treatment combined with high-dose treatment with autologous stem cell transplantation as consolidation on primary central nervous system lymphoma patients. We performed a prospective phase II study for 25 patients with previously untreated primary central nervous system lymphoma. The blood-brain barrier disruption treatment was initiated 3-4 weeks after the MATRix regimen using the previously optimized therapy protocol. Briefly, each chemotherapy cycle included two subsequent intra-arterial blood-brain barrier disruption treatments on days 1 and 2 via either one of the internal carotid arteries or vertebral arteries. Patients received the therapy in 3-week intervals. The treatment was continued for two more courses after achieving a maximal radiological response to the maximum of six courses. The complete treatment response was observed in 88.0% of the patients. At the median follow-up time of 30 months, median progression-free and overall survivals were not reached. The 2-year overall and progression-free survival rates were 67.1% and 70.3%, respectively. Blood-brain barrier disruption treatment is a promising option for primary central nervous system lymphoma with an acceptable toxicity profile.